Nexstim logo

Nexstim Plc hosts pre-surgical TMS symposium at Society for Neuro-Oncology Annual Meeting

24 November 2016

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that it sponsored an educational symposium entitled “The Impact of Pre-Surgical Transcranial Magnetic Stimulation on Glioma Management” at the Society for Neuro-Oncology Annual Meeting, in Scottsdale, Arizona.

Phiroz Tarapore, M.D. from the University of California San Francisco (UCSF), and Sebastian Ille, M.D. from the Technical University of Munich (TUM) described their experiences using Nexstim’s NBS brain mapping system in the diagnosis and treatment of brain tumours and select other applications.

Both UCSF and TUM use the NBS System to gain diagnostic insights in preparation and decision making for surgeries and the overall treatment of patients, incorporating NBS into their diagnostic process for patients with brain tumours and other neurologic disorders.

Commenting on the event, John Liedtky, General Manager U.S. stated: “Nexstim’s NBS systems have now been leading the field in pre-surgical mapping for several years. In this time, the most experienced clinicians have developed a world-recognised expertise. Our goal is to share the extensive clinical experience and techniques using the Nexstim brain mapping technology and we are appreciative of this educational opportunity in collaboration with the Society for Neuro-Oncology.”



Martin Jamieson, Chairman and CEO

Further information is available on the website or by telephone:

Nexstim                                                                                                                   +447715163942

Martin Jamieson, Chairman and CEO                                      

Consilium Strategic Communications                                                                 +44 (0)20 3709 5700

Mary-Jane Elliott / Ivar Milligan / Laura Thornton                   

About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information, please visit

About Transcranial Magnetic Stimulation (TMS)

TMS uses an induction coil in which a time-varying magnetic field is generated to induce an electric E-field within the brain. The neurons at the locations of the brain exposed to a strong enough E-field will become activated, or stimulated. In NBS, the E-field induced in the brain by a TMS induction coil device is shown as an overlay on a graphical display of an anatomical representation of the subject's brain. By viewing the display, a user can visualise the E-field and, therefore, interactively position the TMS coil device, in real time, in relation to the brain to stimulate a target site. The response from the stimulation is measured with an integrated EMG to accurately record the size and latencies MEP caused by the stimulation. To accurately personalise the dose level to each individual the motor threshold needs to be obtained. Optimising E-field generation and individually defining response level an optimal stimulation dose can be accurately and repeatedly administered.

About Society for Neuro-Oncology

The Society for Neuro-Oncology is a multidisciplinary organisation dedicated to promoting advances in neuro-oncology through research and education.

Now in its nineteenth year, the Society continues to grow and mature as the premier North American organisation for clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumours in children and adults.

Press Release - Soc Neuro Oncology SNO Symposium - Final.pdf

Back to Press Releases